↓ Skip to main content

Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory Breast Cancer in In Vivo and In Vitro Models

Overview of attention for article published in PLOS ONE, February 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter
21 X users
facebook
25 Facebook pages
googleplus
2 Google+ users

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
135 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory Breast Cancer in In Vivo and In Vitro Models
Published in
PLOS ONE, February 2013
DOI 10.1371/journal.pone.0057431
Pubmed ID
Authors

Ivette J. Suarez-Arroyo, Raysa Rosario-Acevedo, Alexandra Aguilar-Perez, Pedro L. Clemente, Luis A. Cubano, Juan Serrano, Robert J. Schneider, Michelle M. Martínez-Montemayor

Abstract

The medicinal mushroom Ganoderma lucidum (Reishi) was tested as a potential therapeutic for Inflammatory Breast Cancer (IBC) using in vivo and in vitro IBC models. IBC is a lethal and aggressive form of breast cancer that manifests itself without a typical tumor mass. Studies show that IBC tissue biopsies overexpress E-cadherin and the eukaryotic initiation factor 4GI (eIF4GI), two proteins that are partially responsible for the unique pathological properties of this disease. IBC is treated with a multimodal approach that includes non-targeted systemic chemotherapy, surgery, and radiation. Because of its non-toxic and selective anti-cancer activity, medicinal mushroom extracts have received attention for their use in cancer therapy. Our previous studies demonstrate these selective anti-cancer effects of Reishi, where IBC cell viability and invasion, as well as the expression of key IBC molecules, including eIF4G is compromised. Thus, herein we define the mechanistic effects of Reishi focusing on the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, a regulator of cell survival and growth. The present study demonstrates that Reishi treated IBC SUM-149 cells have reduced expression of mTOR downstream effectors at early treatment times, as we observe reduced eIF4G levels coupled with increased levels of eIF4E bound to 4E-BP, with consequential protein synthesis reduction. Severe combined immunodeficient mice injected with IBC cells treated with Reishi for 13 weeks show reduced tumor growth and weight by ∼50%, and Reishi treated tumors showed reduced expression of E-cadherin, mTOR, eIF4G, and p70S6K, and activity of extracellular regulated kinase (ERK1/2). Our results provide evidence that Reishi suppresses protein synthesis and tumor growth by affecting survival and proliferative signaling pathways that act on translation, suggesting that Reishi is a potential natural therapeutic for breast and other cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 <1%
Unknown 134 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 28 21%
Student > Bachelor 20 15%
Researcher 15 11%
Student > Ph. D. Student 14 10%
Student > Postgraduate 7 5%
Other 21 16%
Unknown 30 22%
Readers by discipline Count As %
Agricultural and Biological Sciences 32 24%
Medicine and Dentistry 21 16%
Biochemistry, Genetics and Molecular Biology 16 12%
Pharmacology, Toxicology and Pharmaceutical Science 7 5%
Psychology 3 2%
Other 18 13%
Unknown 38 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2023.
All research outputs
#1,284,369
of 23,979,422 outputs
Outputs from PLOS ONE
#16,694
of 204,813 outputs
Outputs of similar age
#9,817
of 195,556 outputs
Outputs of similar age from PLOS ONE
#397
of 5,352 outputs
Altmetric has tracked 23,979,422 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 204,813 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,556 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 5,352 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.